30% of surveyed biopharma leaders report that they feel well prepared to address changing trends. Learn 5 elements that can help you act.
Access the insights.
While Sarepta has now consented to the FDA’s request to stop selling Elevidys, the company’s brief standoff with the agency could still carry major consequences for the Duchenne community.
GSK transformed drug development by investing in claims data early and revealing critical treatment dynamics. Learn their approach to securing budget, maximizing ROI and de-risking programs in this webinar.
